JP2015528449A5 - - Google Patents

Download PDF

Info

Publication number
JP2015528449A5
JP2015528449A5 JP2015528817A JP2015528817A JP2015528449A5 JP 2015528449 A5 JP2015528449 A5 JP 2015528449A5 JP 2015528817 A JP2015528817 A JP 2015528817A JP 2015528817 A JP2015528817 A JP 2015528817A JP 2015528449 A5 JP2015528449 A5 JP 2015528449A5
Authority
JP
Japan
Prior art keywords
hepatitis
pharmaceutically acceptable
infection
composition
acceptable agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015528817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528449A (ja
JP6270846B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2013/050377 external-priority patent/WO2014032176A1/en
Publication of JP2015528449A publication Critical patent/JP2015528449A/ja
Publication of JP2015528449A5 publication Critical patent/JP2015528449A5/ja
Application granted granted Critical
Publication of JP6270846B2 publication Critical patent/JP6270846B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015528817A 2012-08-30 2013-05-17 B型肝炎感染及びd型肝炎感染の治療方法 Active JP6270846B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261695040P 2012-08-30 2012-08-30
US61/695,040 2012-08-30
US201261703816P 2012-09-21 2012-09-21
US61/703,816 2012-09-21
PCT/CA2013/050377 WO2014032176A1 (en) 2012-08-30 2013-05-17 Methods for the treatment of hepatitis b and hepatitis d infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017217194A Division JP2018039834A (ja) 2012-08-30 2017-11-10 B型肝炎感染及びd型肝炎感染の治療組成物

Publications (3)

Publication Number Publication Date
JP2015528449A JP2015528449A (ja) 2015-09-28
JP2015528449A5 true JP2015528449A5 (https=) 2016-06-02
JP6270846B2 JP6270846B2 (ja) 2018-01-31

Family

ID=50182316

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015528817A Active JP6270846B2 (ja) 2012-08-30 2013-05-17 B型肝炎感染及びd型肝炎感染の治療方法
JP2017217194A Pending JP2018039834A (ja) 2012-08-30 2017-11-10 B型肝炎感染及びd型肝炎感染の治療組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017217194A Pending JP2018039834A (ja) 2012-08-30 2017-11-10 B型肝炎感染及びd型肝炎感染の治療組成物

Country Status (23)

Country Link
US (4) US9133458B2 (https=)
EP (1) EP2890403A4 (https=)
JP (2) JP6270846B2 (https=)
KR (2) KR20150046309A (https=)
CN (1) CN104837501B (https=)
AU (1) AU2013308045B2 (https=)
BR (1) BR112015003985A2 (https=)
CA (1) CA2883785C (https=)
CL (1) CL2015000499A1 (https=)
CR (1) CR20150107A (https=)
CU (1) CU20150018A7 (https=)
DO (1) DOP2015000041A (https=)
EC (1) ECSP15007345A (https=)
GT (1) GT201500046A (https=)
IL (1) IL237173B (https=)
IN (1) IN2015DN01087A (https=)
MX (1) MX361522B (https=)
MY (1) MY172785A (https=)
NZ (1) NZ705730A (https=)
PH (1) PH12015500361B1 (https=)
SG (1) SG11201501255PA (https=)
TW (1) TWI620568B (https=)
WO (1) WO2014032176A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY168778A (en) 2012-05-18 2018-12-04 Replicor Inc Oligonucleotide chelate complex-polypeptide compositions and methods
AU2013308045B2 (en) 2012-08-30 2018-10-04 Replicor Inc. Methods for the treatment of hepatitis B and hepatitis D infections
HRP20231400T1 (hr) 2014-07-10 2024-02-16 Replicor Inc. Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
US20160175245A1 (en) * 2014-12-19 2016-06-23 Mycotoxins Therapy, Llc Treatment of diseases associated with mold and mycotoxin exposure
JP6924744B2 (ja) 2015-07-17 2021-08-25 アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. B型肝炎ウイルスに対する組成物および薬剤ならびにその使用
US20170137821A1 (en) 2015-07-17 2017-05-18 Arcturus Therapeutics, Inc. Molecules and agents for treating hepatitis b virus
CN108350455A (zh) * 2015-07-29 2018-07-31 阿布特斯生物制药公司 用于使b型肝炎病毒基因表达沉默的组合物和方法
WO2017059878A1 (en) * 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
HK1255835A1 (zh) * 2016-01-08 2019-08-30 Arbutus Biopharma Corporation 用於治疗乙型肝炎的治疗组合物及方法
JP7674628B2 (ja) 2016-02-19 2025-05-12 イーアイティー・ファーマ・インコーポレイテッド インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
US20220265817A1 (en) * 2017-05-31 2022-08-25 Arbutus Biopharma Corporation Therapeutic compositions and methods for treating hepatitis b
TWI815887B (zh) * 2018-05-15 2023-09-21 美商愛彼特生物製藥股份有限公司 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法
EP4512407A3 (en) 2018-07-13 2025-09-24 F. Hoffmann-La Roche AG Oligonucleotides for modulating rtel1 expression
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
MX2021006756A (es) 2018-12-19 2021-09-28 Humabs Biomed Sa Anticuerpos que neutralizan el virus de la hepatitis b y usos de los mismos.
MY206794A (en) 2018-12-20 2025-01-08 Humabs Biomed Sa Combination hbv therapy
EP4081639A1 (en) * 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
CN114507663A (zh) * 2020-11-16 2022-05-17 浙江柏拉阿图医药科技有限公司 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030954A (en) 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US20040054156A1 (en) 1992-05-14 2004-03-18 Kenneth Draper Method and reagent for inhibiting hepatitis B viral replication
US20030206887A1 (en) 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
IL118625A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibodies
CA2254931C (en) * 1996-06-11 2007-04-10 Yeda Research And Development Co. Ltd. Human monoclonal antibodies to the hepatitis b surface antigen
DE19725803C1 (de) 1997-06-18 1999-02-11 Deutsches Krebsforsch HBV-gerichtete Antisense-Nukleinsäuren
IL151981A0 (en) 2000-03-29 2003-04-10 Univ Georgetown Method of treating hepatitis delta viral infection
EP2330194A3 (en) 2002-09-13 2011-10-12 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
US20070027099A1 (en) * 2003-05-19 2007-02-01 Lin Marie C Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA)
HUE042261T2 (hu) 2003-06-12 2019-06-28 Alnylam Pharmaceuticals Inc Gén kikapcsolásra alkalmas konzervált HBV és HCV szekvenciák
CN101084232A (zh) * 2004-10-19 2007-12-05 里普利科股份有限公司 抗病毒寡核苷酸
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
KR20120095397A (ko) * 2009-10-16 2012-08-28 글락소 그룹 리미티드 Hbv 안티센스 억제제
CA2746981A1 (en) * 2010-08-05 2012-02-05 Replicor Inc. Methods for inhibition of apolipoprotein h
BR112013003875B1 (pt) * 2010-08-20 2021-10-05 Replicor Inc Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos
WO2012047856A2 (en) 2010-10-04 2012-04-12 Institute For Hepatitis And Virus Research Novel inhibitors of secretion of hepatitis b virus antigens
PH12019502377A1 (en) 2011-04-21 2022-11-14 Isis Pharmaceuticals Inc Modulation of hepatitis b virus (hbv) expression
HRP20181564T1 (hr) 2011-06-30 2018-11-30 Arrowhead Pharmaceuticals, Inc. Pripravci i postupci za inhibiciju ekspresije gena virusa hepatitisa b
AR091065A1 (es) 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
MY168778A (en) * 2012-05-18 2018-12-04 Replicor Inc Oligonucleotide chelate complex-polypeptide compositions and methods
AU2013308045B2 (en) 2012-08-30 2018-10-04 Replicor Inc. Methods for the treatment of hepatitis B and hepatitis D infections

Similar Documents

Publication Publication Date Title
JP2015528449A5 (https=)
JP6922030B2 (ja) B型肝炎およびd型肝炎ウイルス感染の治療のための方法
TWI620568B (zh) 用於治療b型肝炎及d型肝炎感染之方法
JP2021533767A5 (https=)
Ma et al. Toward a functional cure for hepatitis B: the rationale and challenges for therapeutic targeting of the B cell immune response
FI3837366T3 (fi) Hepatiitti b -viruksen (hbv) dsrna-ainekoostumuksia ja niiden käyttömenetelmiä
JP2013522302A5 (https=)
WO2018087345A1 (en) COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
JP2017521433A5 (https=)
JP2019533472A5 (https=)
JP2015517504A5 (https=)
Stein et al. Drug targets in hepatitis B virus infection
JPWO2020036862A5 (https=)
De Clercq Interferon and its inducers—a never-ending story:“old” and “new” data in a new perspective
JP2022548652A (ja) コアタンパク質アロステリックモジュレータを使用してhbv感染を処置する方法
CN114057816B (zh) 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
Seto et al. Future prevention and treatment of chronic hepatitis B infection
HK40065449A (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
Korkmaz et al. Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients